Stay updated with breaking news from Ajay Nirula. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Phase 1b Safety and Efficacy Data for Rezpegaldesleukin in Moderate to Severe Atopic Dermatitis to be Presented in Late-Breaking Oral Presentation – SAN FRANCISCO, Oct. 2, 2023 /PRNewswire/ --...
Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE). The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to ...
INDIANAPOLIS, Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company today announced the successful completion of its acquisition of DICE Therapeutics, Inc. . The acquisition expands Lilly's immunology...
This is the first clinical evidence to show that stimulating the programmed cell death protein 1 (PD1) inhibitory pathway is beneficial for rheumatologic disease.
Results of a Phase 2a clinical trial suggest that peresolimab, an antibody that stimulates the human death protein 1 (PD-1) pathway, could be a promising new approach for the treatment of rheumatoid arthritis.